Compounds > 6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline)
Page last updated: 2024-08-26

6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline) and Uterine Neoplasms

6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline) has been researched along with Uterine Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bär-Pollák, Z; Kovács, G; Németh, G1

Trials

1 trial(s) available for 6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline) and Uterine Neoplasms

ArticleYear
[Clinical experiences with the radiation sensitizer MTDQ (Sensorad) in advanced malignancies of the head and neck region and in uterine cancer].
    Strahlentherapie, 1984, Volume: 160, Issue:10

    Topics: Clinical Trials as Topic; Double-Blind Method; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Placebos; Quinolines; Radiation Dosage; Radiation Injuries; Uterine Neoplasms

1984